Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M. Freyer G, et al. Among authors: selle f. Nat Commun. 2024 Jun 4;15(1):4753. doi: 10.1038/s41467-024-48915-9. Nat Commun. 2024. PMID: 38834579 Free PMC article. No abstract available.
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A. O'Cearbhaill RE, et al. Among authors: selle f. Gynecol Oncol. 2022 Jul;166(1):36-43. doi: 10.1016/j.ygyno.2022.04.012. Epub 2022 May 9. Gynecol Oncol. 2022. PMID: 35550709 Free PMC article. Clinical Trial.
[Dose density and dose intensity in the treatment of breast cancer].
Saintigny P, Assouad S, Gligorov J, Selle F, Roché H, Breau JL, Morère JF, Lotz JP. Saintigny P, et al. Among authors: selle f. Bull Cancer. 2004 Dec 1;91 Suppl 4:S244-53. Bull Cancer. 2004. PMID: 15899616 Free article. Review. French.
Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy.
Lüftner D, Dell'Acqua V, Selle F, Khalil A, Leonardi MC, De La Torre Tomás A, Shenouda G, Romero Fernandez J, Orecchia R, Moyal D, Seité S. Lüftner D, et al. Among authors: selle f. Onco Targets Ther. 2018 Sep 17;11:5865-5872. doi: 10.2147/OTT.S155438. eCollection 2018. Onco Targets Ther. 2018. PMID: 30271169 Free PMC article.
[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].
Launay-Vacher V, Janus N, Beuzeboc P, Daniel C, Ray-Coquard I, Selle F, Rey JB, Jouannaud C, Spano JP, Thery JC, Morere JF, Goldwasser F, Mir O, Oudard S, Scotté F, Dorent R, Ludwig L, Deray G, Gligorov J. Launay-Vacher V, et al. Among authors: selle f. Bull Cancer. 2015 Nov;102(11):906-14. doi: 10.1016/j.bulcan.2015.09.001. Bull Cancer. 2015. PMID: 26603517 French.
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. Among authors: selle f. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
121 results